Company Overview

Update
Headquarters:
Berkeley Heights, NJ
IPO:
Went Public on Apr 7, 2006
Stock:
CYCC
Categories:
Biotechnology
Description:
Cyclacel Pharmaceuticals develops oral therapies to treat cancers and other critical diseases.

Detailed Description

Update

Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Professor Sir David Lane, a recognized leader in the field of tumor suppressor biology, who discovered the p53 protein, founded the Company in 1996. In 1999, Cyclacel Pharmaceuticals was joined by Professor David Glover, a recognized leader in the mechanism of mitosis or cell division, who discovered, among other cell cycle targets, the mitotic kinases, Polo and Aurora, enzymes that act in the mitosis phase of the cell cycle.

Current Team (4)

Update

Funding Rounds (7) - $132.2M

Update

Board Members and Advisors (1)

Update

Investors (1)

Update
  • B4fda521d4ea324ad7f11ad01713acaf

    Scottish Equity Partners

    Scottish Equity Partners is a venture capital firm investing in technology-based companies in the...

Offices/Locations (1)

Update
  • Headquarters

    200 Connell Drive #1500

    Berkeley Heights, NJ 07922

    USA

Images (1)

Update
  • Ksjtiy39uggbkstdcyu9